This initiative provides early-stage translational support to identify and characterize potential therapeutic candidates and combination products for HLBS diseases and disorders. It aims to facilitate the transition from basic science discoveries to viable diagnostics and therapeutics cleared for human testing, focusing on product development and entrepreneurship without supporting clinical trials.
Eligible applicants include a wide range of organizations such as county and state governments, institutions of higher education, nonprofits, tribal organizations, small businesses, and federal agencies. Non-domestic entities are generally not eligible, but foreign components of U.S. organizations a
